Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 21 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2015KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategyYeung, D.; Tang, C.; Vidovic, L.; White, D.; Branford, S.; Hughes, T.; Yong, A.
2017CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patientsBarratt, D.; Cox, H.; Menelaou, A.; Yeung, D.; White, D.; Hughes, T.; Somogyi, A.
2012Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemiaYeung, D.; Hughes, T.
2012BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and managementBranford, S.; Yeung, D.; Prime, J.; Choi, S.; Bang, J.; Park, J.; Kim, D.; Ross, D.; Hughes, T.
2014Achieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepointBranford, S.; Ross, D.; Yeung, D.; Braley, J.; Hughes, T.; 56th ASH Annual Meeting (6 Dec 2014 - 9 Dec 2014 : San Francisco, California)
2014Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineBranford, S.; Yeung, D.; Parker, W.; Roberts, N.; Purins, L.; Braley, J.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Donaldson, Z.; Leong, M.; Fletcher, L.; Seymour, J.; Grigg, A.; Ross, D.; Hughes, T.
2010Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trialYeung, D.; Osborn, M.; White, D.; Branford, S.; Haswell, L.; Slader, C.; Issa, S.; Hiwase, D.; Hertzberg, M.; Schwarer, A.; Filshie, R.; Arthur, C.; Kwan, Y.; Forsyth, C.; Ross, D.; Mills, A.; Grigg, A.; Hughes, T.; Annual Meeting of the American Society of Hematology (52nd : 2010 : Orlando, Fl.)
2018Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expressionMcClure, B.; Heatley, S.; Kok, C.; Sadras, T.; An, J.; Hughes, T.; Lock, R.; Yeung, D.; Sutton, R.; White, D.
2017Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesionsSadras, T.; Heatley, S.; Kok, C.; Dang, P.; Galbraith, K.; McClure, B.; Muskovic, W.; Venn, N.; Moore, S.; Osborn, M.; Revesz, T.; Moore, A.; Hughes, T.; Yeung, D.; Sutton, R.; White, D.
2013BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistanceParker, W.; Yeoman, A.; Jamison, B.; Yeung, D.; Scott, H.; Hughes, T.; Branford, S.